skip to content

Yusuf Hamied Department of Chemistry

 
Portrait of ab454

Reader for Molecular Informatics

Associate Director Computational ADME and Safety (Clinical Pharmacology & Safety Sciences/Data Science and Artificial Intelligence - CPSS/DSAI) at AstraZeneca Cambridge

Co-founder of Healx Ltd.

Co-founder of PharmEnable Ltd.

Personal Website

  • Committed to developing new life science data analysis methods (AI/ML/data science) and their application, primarily related to chemical biology, drug discovery and in silico toxicology
  • Expertise comprises data ranging from chemical structure and gene expression data to phenotypic readouts and preclinical information, applied to both efficacy- and safety/tox-related questions
  • Collaborating with academic research groups, as well as  pharmaceutical, chemical, and consumer goods companies (Eli Lilly, AstraZeneca, GSK, BASF, Johnson&Johnson/Janssen, Unilever, ...)
  • Co-founder/founding CTO and current SAB member of Healx Ltd. (data-driven drug repurposing for rare diseases, and beyond); co-founder of PharmEnable Ltd.; SAB member of Lhasa Ltd. (toxicology and metabolism prediction) and Cresset Ltd.
  • Coordinator of the Computational & In Silico Toxicology Specialty Section of the British Toxicology Society (BTS)
  • Steering Committee Member of the Cambridge Alliance on Medicines Safety (CAMS)
  • Currently leading a group of ca. 15 PhD students, postdocs, project students and visitors at the Centre for Molecular Informatics at the University of Cambridge, https://www-cmi.ch.cam.ac.uk/centre-molecular-informatics

Publications

Systematic Analysis of Protein Targets Associated with Adverse Events of Drugs from Clinical Trials and Postmarketing Reports.
IA Smit, AM Afzal, CHG Allen, F Svensson, T Hanser, A Bender
– Chemical Research in Toxicology
(2020)
acs.chemrestox.0c00294
New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets
KA Giblin, D Basili, AM Afzal, L Rosenbrier-Ribeiro, N Greene, I Barrett, SJ Hughes, A Bender
– Chemical research in toxicology
(2020)
acs.chemrestox.0c00311
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet
A Bender, I Cortés-Ciriano
– Drug discovery today
(2020)
Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells
L-L Pruteanu, L Kopanitsa, D Módos, E Kletnieks, E Samarova, A Bender, LD Gomez, DS Bailey
– PLoS One
(2020)
15,
e0239551
Comparison of scaling methods to obtain calibrated probabilities of activity for protein-ligand predictions
LH Mervin, AM Afzal, O Engkvist, A Bender
– Journal of chemical information and modeling
(2020)
60,
4546
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.
I Ayestaran, A Galhoz, E Spiegel, B Sidders, JR Dry, F Dondelinger, A Bender, U McDermott, F Iorio, MP Menden
– Patterns (New York, N.Y.)
(2020)
1,
100065
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports
I Smit, A Afzal, C Allen, F Svensson, T Hanser, A Bender
(2020)
QSAR-derived affinity fingerprints (part 2): Modeling performance for potency prediction
I Cortés-Ciriano, C Škuta, A Bender, D Svozil
– J Cheminform
(2020)
12,
41
QSAR-derived affinity fingerprints (part 1): fingerprint construction and modeling performance for similarity searching, bioactivity classification and scaffold hopping
C Škuta, I Cortés-Ciriano, W Dehaen, P Kříž, GJP van Westen, IV Tetko, A Bender, D Svozil
– Journal of cheminformatics
(2020)
12,
39
EMDIP: An Entropy Measure to Discover Important Proteins in PPI networks
H Bashiri, H Rahmani, V Bashiri, D Módos, A Bender
– Computers in Biology and Medicine
(2020)
120,
103740
  • 1 of 33
  • >

Research Group

Research Interest Groups

Telephone number

01223 762983

Email address

ab454@cam.ac.uk